Cas:847729-02-6 tert-butyl 4-[(1S)-1-aminoethyl]benzoate manufacturer & supplier

Chemical Name:tert-butyl 4-[(1S)-1-aminoethyl]benzoate

CAS.NO:847729-02-6

Synonyms:tert-butyl 4-[(1S)-1-aminoethyl]benzoate

Molecular Formula:C₁₃H₁₉NO₂

Molecular Weight:221.29500

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:52.32000

Exact Mass:221.14200

LogP:3.36190

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like tert-butyl 4-[(1S)-1-aminoethyl]benzoate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,tert-butyl 4-[(1S)-1-aminoethyl]benzoate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,tert-butyl 4-[(1S)-1-aminoethyl]benzoate Use and application,tert-butyl 4-[(1S)-1-aminoethyl]benzoate technical grade,usp/ep/jp grade.

Related News: Onconova Therapeutics, Inc. is a Phase 3-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with an initial focus on Myelodysplastic Syndromes (MDS). tert-butyl 4-[(1S)-1-aminoethyl]benzoate manufacturer It wasn’t known if this was due to racial differences in breast cancer-related genetic mutations, making it unclear whether race should help guide genetic testing. tert-butyl 4-[(1S)-1-aminoethyl]benzoate supplier ��Administrative Measures for the Joint Review, Review and Approval of Raw Materials, Medicinal Auxiliaries and Pharmaceutical Packaging Materials and Pharmaceutical Preparations�� (Consultation Draft) issued by the State Food and Drug Administration in December 2017. Supervision departments no longer accept applications for registration of APIs, pharmaceutical excipients, and packaging materials. tert-butyl 4-[(1S)-1-aminoethyl]benzoate vendor This dosage form may also support combination therapy modalities.? To date, over 400 patients have been dosed with the oral formulation of rigosertib in clinical trials.? Combination therapy of oral rigosertib with azacitidine, the standard of care in HR-MDS, has also been studied. Currently, oral rigosertib is being developed as a combination therapy together with azacitidine for patients with higher-risk MDS who require HMA therapy.? tert-butyl 4-[(1S)-1-aminoethyl]benzoate factory Myelodysplastic syndromes (MDS) are conditions that can occur when the blood-forming cells in the bone marrow become dysfunctional and thus produce an inadequate number of circulating blood cells.